Kane to Host Investor Webinar – What Kane has in Store for 2025 Including the Acquisition of FB Dermatology
Kane Biotech (TSX-V:KNE; OTCQB:KNBIF) announced a webinar scheduled for January 23rd, 2025, where CEO Marc Edwards and Executive Chairman Dr. Robert Huizinga will discuss the company's 2025 outlook. The presentation will build on key 2024 achievements, including: the scale-up manufacturing of revyve™ Antimicrobial Wound Gel Spray, securing new US distribution partnerships, obtaining Health Canada Approval, and agreeing to acquire FB Dermatology to expand presence in EU, Australia, and New Zealand.
Notable 2024 milestones also included participation in NRC-IRAP projects, distribution agreements in UAE and Qatar, FDA approval for increased dosage allowance, ISO 13485:2016 MDSAP certification, and the $12.5M USD sale of STEM Animal Health to Dechra Veterinary Products. Additionally, Kane announced a six-month marketing service agreement with Outside The Box Capital for $100,000 to enhance their market visibility.
Kane Biotech (TSX-V:KNE; OTCQB:KNBIF) ha annunciato un webinar programmato per il 23 gennaio 2025, durante il quale il CEO Marc Edwards e il Presidente esecutivo Dr. Robert Huizinga discuteranno le prospettive dell'azienda per il 2025. La presentazione si concentrerà sui principali traguardi del 2024, tra cui: il potenziamento della produzione di revyve™ Antimicrobial Wound Gel Spray, la conclusione di nuove partnership di distribuzione negli Stati Uniti, il conseguimento dell'approvazione da parte di Health Canada e l'accordo per acquisire FB Dermatology per ampliare la presenza nell'UE, in Australia e in Nuova Zelanda.
I traguardi significativi del 2024 hanno incluso anche la partecipazione a progetti NRC-IRAP, accordi di distribuzione negli Emirati Arabi Uniti e in Qatar, l'approvazione della FDA per un incremento della dose consentita, la certificazione ISO 13485:2016 MDSAP e la vendita di 12,5 milioni di dollari USA di STEM Animal Health a Dechra Veterinary Products. Inoltre, Kane ha annunciato un accordo di servizio di marketing di sei mesi con Outside The Box Capital per $100,000 al fine di migliorare la loro visibilità sul mercato.
Kane Biotech (TSX-V:KNE; OTCQB:KNBIF) anunció un seminario web programado para el 23 de enero de 2025, donde el CEO Marc Edwards y el Presidente Ejecutivo Dr. Robert Huizinga discutirán las perspectivas de la empresa para 2025. La presentación se basará en los logros clave de 2024, que incluyen: la ampliación de la fabricación del aerosol de gel antimicrobiano revyve™, el aseguramiento de nuevas alianzas de distribución en EE. UU., la obtención de la aprobación de Health Canada y el acuerdo para adquirir FB Dermatology para expandir su presencia en la UE, Australia y Nueva Zelanda.
Los hitos notables de 2024 también incluyeron la participación en proyectos NRC-IRAP, acuerdos de distribución en los EAU y Qatar, la aprobación de la FDA para un aumento en la dosis permitida, la certificación ISO 13485:2016 MDSAP y la venta de 12.5 millones de dólares estadounidenses de STEM Animal Health a Dechra Veterinary Products. Además, Kane anunció un acuerdo de servicio de marketing de seis meses con Outside The Box Capital por $100,000 para mejorar su visibilidad en el mercado.
Kane Biotech (TSX-V:KNE; OTCQB:KNBIF)는 2025년 1월 23일로 예정된 웨비나를 발표했습니다. 이 자리에서 CEO인 Marc Edwards와 의장 Dr. Robert Huizinga는 회사의 2025년 전망에 대해 논의할 것입니다. 이 프레젠테이션은 2024년의 주요 성과를 기반으로 하며, 여기에는 revyve™ 항균 상처 젤 스프레이의 생산 확대, 미국 내 새로운 유통 파트너십 확보, Health Canada 승인 획득, 그리고 FB Dermatology 인수를 통한 EU, 호주, 뉴질랜드 내 존재 확장이 포함됩니다.
2024년의 주요 이정표에는 NRC-IRAP 프로젝트 참여, UAE 및 카타르에서의 유통 계약, FDA의 용량 증가 허가, ISO 13485:2016 MDSAP 인증, 그리고 STEM Animal Health를 Dechra Veterinary Products에 1,250만 달러에 판매한 것이 포함됩니다. 추가로, Kane은 Outside The Box Capital과 10만 달러에 6개월 마케팅 서비스 계약을 체결하여 시장 내 가시성을 높여 나갈 것이라고 발표했습니다.
Kane Biotech (TSX-V:KNE; OTCQB:KNBIF) a annoncé un webinaire prévu pour le 23 janvier 2025, au cours duquel le PDG Marc Edwards et le président exécutif Dr. Robert Huizinga discuteront des perspectives de l'entreprise pour 2025. La présentation s'appuiera sur les réalisations clés de 2024, notamment : l'augmentation de la production du spray gel antimicrobien revyve™, la sécurisation de nouveaux partenariats de distribution aux États-Unis, l'obtention de l'approbation de Health Canada et l'accord d'acquérir FB Dermatology pour étendre sa présence en UE, en Australie et en Nouvelle-Zélande.
Les jalons notables de 2024 comprenaient également la participation à des projets NRC-IRAP, des accords de distribution aux EAU et au Qatar, l'approbation de la FDA pour une augmentation de la posologie autorisée, la certification ISO 13485:2016 MDSAP et la vente de 12,5 millions USD de STEM Animal Health à Dechra Veterinary Products. De plus, Kane a annoncé un contrat de service marketing de six mois avec Outside The Box Capital pour 100 000 USD afin d'améliorer sa visibilité sur le marché.
Kane Biotech (TSX-V:KNE; OTCQB:KNBIF) hat ein Webinar für den 23. Januar 2025 angekündigt, in dem CEO Marc Edwards und der Executive Chairman Dr. Robert Huizinga die Aussichten des Unternehmens für 2025 diskutieren werden. Die Präsentation wird sich auf die wichtigsten Erfolge von 2024 stützen, darunter: die Skalierung der Produktion des revyve™ Antimikrobielle Wundgel-Sprays, den Abschluss neuer Vertriebspartnerschaften in den USA, den Erhalt der Genehmigung von Health Canada sowie die Vereinbarung zur Übernahme von FB Dermatology zur Erweiterung der Präsenz in der EU, Australien und Neuseeland.
Zu den bemerkenswerten Meilensteinen von 2024 gehörten auch die Teilnahme an NRC-IRAP-Projekten, Vertriebsverträge in den VAE und Katar, die FDA-Genehmigung für eine erhöhte Dosiszulassung, die ISO 13485:2016 MDSAP-Zertifizierung sowie der Verkauf von STEM Animal Health für 12,5 Millionen USD an Dechra Veterinary Products. Darüber hinaus hat Kane einen sechsmonatigen Marketingdienstvertrag mit Outside The Box Capital im Wert von 100.000 USD abgeschlossen, um ihre Marktpräsenz zu erhöhen.
- Sale of STEM Animal Health division for $12.5M USD to Dechra Veterinary Products
- Geographic expansion through FB Dermatology acquisition into EU, Australia, and New Zealand markets
- Regulatory approvals: Health Canada and FDA increased dosage allowance for revyve™ product
- New distribution partnerships in US, UAE, and Qatar markets
- Obtained ISO 13485:2016 MDSAP Quality Certification
- Marketing expenses of $100,000 for six-month OTBC service agreement
Thursday, January 23rd, 2025 at 4:15pm Eastern Time
WINNIPEG, Manitoba, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane”) announces that it will be hosting a webinar on Thursday, January 23, 2025 at 4:15pm Eastern Time.
Participants can register for the webinar by using this link: Kane Webinar – Jan 23, 2025
Marc Edwards, President and CEO, along with Dr. Robert Huizinga, Executive Chairman will update investors as to what they should expect in 2025, building on the achievement of key milestones in 2024 which included:
- Completion of the scale-up manufacturing of revyve™ Antimicrobial Wound Gel Spray
- New US distribution partner for revyve™ Antimicrobial Wound Gel
- Health Canada Approval of revyve™ Antimicrobial Wound Gel, and ramp up of Canadian Commercial activities
- Agreement to acquire FB Dermatology, increasing our sales presence in the EU, Australia and New Zealand
- Participation in the NRC-IRAP Multinational Corporate Collaboration project along with an unnamed large global wound care company
- Distribution agreements with Razan Medical Trading (UAE) and Qatar Datamation Systems (Qatar) allowing for sales of revyve™ Antimicrobial Wound Gel in the GCC
- NRC-IRAP funding to support the expansion of the revyve™ Antimicrobial Wound Gel family
- FDA Approval to Increase Dosage Allowance for our revyve™ Antimicrobial Wound Gel, which allows for the use of our spray gel
- Receiving ISO 13485:2016 MDSAP Quality Certification which is the result of years of hard work that led to our Health Canada approval for revyve™, and the potential of sales in Australia and New Zealand
- First commercial sale of revyve™ Antimicrobial Wound Gel in Q3 to ProgenaCare Global
- The
$12.5M USD sale of STEM Animal Health to Dechra Veterinary Products, which speaks to the quality of our technology across multiple platforms.
Kane also announces today that it has entered into a six-month service agreement (the “OTBC Service Agreement”) with independent marketing firm Outside The Box Capital (“OTBC”) to provide marketing services to communicate information about Kane to the financial community, commencing on January 17, 2025. These marketing services include digital marketing through various social media channels to broaden media distribution awareness about the Company. Pursuant to the OTBC Service Agreement, OTBC received
About Kane Biotech
Kane Biotech Inc. is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Kane has a portfolio of biotechnologies, intellectual property (65 patents and patents pending as well as trade secrets and trademarks) and products developed by Kane's own biofilm research expertise and acquired from leading research institutions. DispersinB®, coactiv+™, coactiv+®, DermaKB™, DermaKB Biofilm™, and revyve™ are trademarks of Kane Biotech Inc. Kane is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
For more information:
| Marc Edwards | Ray Dupuis | ||||
| Chief Executive Officer | Chief Financial Officer | ||||
| Kane Biotech Inc | Kane Biotech Inc | ||||
| medwards@kanebiotech.com | rdupuis@kanebiotech.com | ||||
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to Kane’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of Kane to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by Kane with applicable securities regulatory authorities, available at www.sedarplus.ca. Kane cautions that the foregoing list of factors that may affect future results is not exhaustive.
FAQ
What was the value of Kane Biotech's (KNBIF) STEM Animal Health sale to Dechra?
What markets will Kane Biotech (KNBIF) expand into through the FB Dermatology acquisition?
What regulatory approvals did Kane Biotech (KNBIF) receive for revyve™ in 2024?
Which new distribution partnerships did Kane Biotech (KNBIF) secure in 2024?
How much did Kane Biotech (KNBIF) spend on marketing services with Outside The Box Capital?
